10X Genomics
10x Genomics (NASDAQ: TXG) develops single-cell and spatial biology instruments and consumables — Chromium, Atera, Xenium, and Visium — used by academic, biopharmaceutical, and clinical researchers to profile gene and protein expression at single-cell resolution.
- Company typePublic
- Founded2015
- HeadquartersPleasanton, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What 10X Genomics does
10x Genomics is a publicly traded life-science tools company (NASDAQ: TXG) that develops single-cell and spatial biology platforms used by academic researchers, biopharmaceutical companies, and clinical institutions to profile gene expression, protein expression, and chromatin state at single-cell and subcellular resolution. Its instrument portfolio centers on four platforms: Chromium Single Cell (droplet-based single-cell multiomics powered by GEM-X microfluidic technology with up to 80% cell recovery and 95% usable reads), Atera In Situ (whole-transcriptome spatial platform launched April 2026 with throughput of up to 800 1 cm² samples per year), Xenium In Situ (high-plex subcellular imaging of up to 5,000 RNA targets), and Visium Spatial (NGS-based spatial gene expression with the CytAssist instrument). Chemistries include Flex Apex (plate-based multiplexing of up to 384 samples or 100 million cells per week for FFPE and fixed whole blood), Universal 3'/5', and Epi multiome assays, complemented by free software pipelines (Cell Ranger, Space Ranger, Loupe Browser, Xenium Explorer) and cloud analysis tools.
The company makes money primarily by selling capital instruments and a recurring stream of consumables (reagents, assay kits, panels, and microfluidic chips) that drive the bulk of revenue; consumables grew to $598.7M in FY2025 while instruments declined 39% as customers worked through installed-base capacity. Distribution combines a global direct enterprise sales force for large pharmaceutical and academic accounts, a regional distributor network including Asia-Pacific, an e-commerce store for mid-market consumables purchases, and service-provider partners such as Macrogen/Psomagen that operate 10x instruments on behalf of researchers who do not want to buy capital equipment. Customers include biopharmaceutical companies (drug discovery, biomarker, and trial-design applications), academic and research institutions (cancer, immunology, neuroscience, developmental biology), and an emerging clinical healthcare segment, with a pipeline of major partnerships including the STELA atlas with Bioptimus, the Billion Cells Project with the Chan Zuckerberg Initiative, and the ImmuneScape initiative with CareDx.
10x Genomics is incorporated in the United States, headquartered in Pleasanton, California, and employs 1,001-5,000 people. It went public on NASDAQ in September 2019 and has since used M&A to extend its technology footprint, acquiring Spatial Transcriptomics (2018), EPINOMICS (2018), ReadCoor (2020), CARTANA (2020), Tetramer Shop (2021), Scale Biosciences (2025), and Proteintech Genomics (2026) to add spatial, epigenomic, and proteomic capabilities.
10X Genomics firmographics
Firmographics- Name
- 10X Genomics
- Legal name
- 10x Genomics, Inc.
- Website
- https://10xgenomics.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- 10x Genomics (NASDAQ: TXG) develops single-cell and spatial biology instruments and consumables — Chromium, Atera, Xenium, and Visium — used by academic, biopharmaceutical, and clinical researchers to profile gene and protein expression at single-cell resolution.
- Ownership category
- akta.pro rank
10X Genomics industry classification
Industry- Product category
- Life Sciences Research Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417), Medical Laboratories (621511)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where 10X Genomics is headquartered
LocationHeadquarters
- HQ city
- Pleasanton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
10X Genomics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Instrument Sales: Sale of capital equipment including Chromium instruments (X Series, Controller, Connect), Atera spatial platform, Xenium Analyzer, and Visium CytAssist. Instrument revenue declined 39% year-over-year in FY2025.
- Consumables: Recurring revenue from reagents, assay kits, and consumables for single cell and spatial biology assays including Flex, Universal 3'/5', Epi kits, Xenium panels, and Visium reagents. Consumables revenue grew 3% in FY2025 to $598.7 million (underlying, excluding patent settlement).
- Software and Analysis: Revenue from software products including Cell Ranger, Space Ranger, Loupe Browser, Xenium Explorer, and cloud-based analysis tools. Software includes free pipelines with premium features and cloud services.
- CLIA Laboratory Services: Future revenue stream from plans to build CLIA-certified laboratory for clinical diagnostic services, supporting assay implementation and clinical sample processing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Enterprise instrumentation with customized pricing |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
10X Genomics product offering
Product offeringCore offering
10X Genomics develops and commercializes integrated platforms for single-cell and spatial biology, combining proprietary instruments (Chromium, Atera, Xenium, Visium), assay chemistries (Flex, Universal 3'/5', Epi), and software (Cell Ranger, Loupe Browser, Cloud Analysis, Space Ranger, Xenium Explorer). Products enable researchers to profile gene expression at single-cell resolution across thousands of samples, supporting cancer research, immunology, neuroscience, drug discovery, and translational medicine applications. Revenue is generated through instrument sales and a recurring consumables and software stream tied to installed platforms.
Product overview
10x Genomics is a life science technology company offering a comprehensive portfolio of single-cell and spatial biology platforms. The product portfolio centers on four core instrument platforms: Chromium Single Cell (droplet-based single-cell analysis), Atera In Situ (next-generation whole-transcriptome spatial platform), Xenium In Situ (high-plex spatial imaging), and Visium Spatial (NGS-based spatial analysis). These are complemented by assay chemistries including Flex Apex (probe-based, plate-multiplexed), Universal 3'/5' (transcriptome-based), and Epi kits for chromatin analysis. A comprehensive software ecosystem includes Cell Ranger, Cloud Analysis, Loupe Browser, Space Ranger, and Xenium Explorer for data processing and visualization. The company serves academic, translational, and biopharmaceutical researchers across cancer research, immunology, neuroscience, and developmental biology applications.
Differentiator
Problem solved
Functional benefit
Brands
- Atera: Next-generation in situ spatial biology platform for whole-transcriptome spatial analysis with single-cell sensitivity at scale.
- Flex Apex
- Chromium
- Xenium
- Visium
Products and services
- Chromium Single Cell
Quantifiable outcome
- Up to 80% cell recovery efficiency
- +5 more outcomes
Companies that use 10X Genomics
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
10X Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability6 records
Feature6 records
10X Genomics partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core, minor and flagship.
- Cleveland CliniccoreMulti-year research collaboration focused on bladder cancer diagnostics using single-cell, spatial transcriptomic, and protein profiling technologies to build multimodal cancer datasets linking molecular data with clinical outcomes
- Proteintech GenomicscoreAcquisition expanding 10x Genomics' proteomics capabilities, adding the Human Discovery Panel and antibody-based single-cell protein panels compatible with Flex chemistry workflows for enhanced multiomic analysis
- AnthropiccoreIntegration of 10x Genomics analysis tools into Anthropic's Claude for Life Sciences platform, enabling AI-powered analysis of single cell and spatial biology data
- BioptimuscoreStrategic partnership anchoring the STELA spatial biology initiative to profile up to 100,000 patient tissue specimens across US, Europe, and Asia using the Xenium platform, creating data backbone for Bioptimus's M-Optimus world model of biology
- Broad Clinical LabscorePartnership in STELA initiative contributing high-throughput data generation capabilities for the 100,000-specimen spatial biology atlas spanning three continents
- PerturbAIminorCollaboration providing 10x Genomics technology for PerturbAI's 8 million-cell brain-wide CRISPR atlas generated using in vivo Perturb-seq technology for AI-driven drug discovery
- RochecorePartnership to develop single-cell kits for Roche's AXELIOS 1 sequencer platform, integrating 10x Genomics technology into Roche's diagnostic ecosystem
- PharosAIflagshipUK consortium partnership using Xenium spatial platform to build one of the world's most comprehensive multimodal cancer datasets from archived NHS samples, backed by £18.9 million UK government funding, initially focusing on breast cancer expanding to lung and pancreatic cancer through 2027
- Dana-Farber Cancer InstituteflagshipMulti-year collaboration analyzing tumor samples from patients with major solid cancers using Chromium Flex single cell assay and Xenium spatial platform to identify biological features associated with treatment response and resistance
- Brigham and Women's HospitalflagshipStudy analyzing blood samples from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis using Chromium Flex single-cell assay to identify immune signatures for personalized autoimmune disease management
- Cancer Research InstituteflagshipMulti-phase collaboration building one of the world's largest AI-driven immuno-oncology datasets profiling over 20,000 samples to map the immune landscape of cancer and accelerate immunotherapy discovery
- CareDxflagshipLaunch of ImmuneScape multiomics research initiative to decode transplant rejection and drug response using Xenium spatial and Chromium Flex single cell platforms, building on CareDx's HistoMap Kidney product
- Arc InstituteflagshipVirtual Cell Atlas collaboration generating 300M+ cell CRISPR perturbational dataset using Flex technology to fuel AI cell models predicting cellular responses for therapeutic target discovery
- Chan Zuckerberg InitiativeflagshipBillion Cells Project creating landmark single cell dataset using Chromium technology to deepen understanding of cellular behavior and gene function for AI model training
- OwkinflagshipMOSAIC pan-cancer spatial transcriptomics initiative using Visium and Flex technologies to enable AI-based therapeutic prediction modeling with 7,000 FFPE tissues
- A*STAR Genome Institute of SingaporeflagshipTISHUMAP study using Xenium platform for large-scale spatial omics enabling drug target discovery with 2,500 FFPE tissues
- Xaira TherapeuticsflagshipX-Atlas/Orion project generating largest publicly available Perturb-seq atlas targeting all human protein-coding genes for foundational model training using Universal 5' technology with 8M cells
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
10X Genomics competitors and assessment
Company assessmentDirect peers
- NanoString Technologies (acquired by Bruker): Direct competitor in spatial transcriptomics through the CosMx SMI (single-cell) and GeoMx (tissue) platforms. Now operating under Bruker's Spatial Biology division, NanoString is 10x's principal head-to-head rival in the spatial biology market.
- Vizgen: Direct competitor in spatial transcriptomics with the MERFISH platform, offering high-plex in situ gene expression profiling. Competes directly with 10x's Xenium and Atera platforms for translational and academic spatial biology customers.
- Akoya Biosciences: Spatial biology competitor offering the PhenoCycler (CODEX) multiplexed spatial proteomics platform and Phenoptics tissue imaging solutions. Competes with 10x's Xenium and Visium in immuno-oncology and translational research workflows.
- Bio-Techne: Competitor in single-cell and spatial consumables, including the RNAscope in situ hybridization product line and ProteinSimple instruments. Overlaps with 10x on consumables sold to academic and translational research customers.
- Standard BioTools (formerly Fluidigm): Single-cell analysis competitor with the Hyperion imaging mass cytometry and legacy CyTOF / mass cytometry products. Competes with 10x Chromium in immunology and oncology research, especially in multiomic protein profiling.
Broad incumbents
- Illumina: Dominant sequencing platform provider that is both a critical downstream dependency for 10x Chromium/Visium workflows and a broader competitor through its own single-cell and spatial initiatives (e.g., Illumina Connected Multiomics). Strategic partner and ecosystem competitor.
- Revvity (formerly PerkinElmer Life Sciences): Diversified life science tools and reagents provider with overlapping offerings in spatial biology, genomics workflows, and clinical diagnostics. Competes with 10x in reagent and consumables categories through its life sciences segment.
- Pacific Biosciences: Long-read sequencing platform provider with emerging single-cell and HiFi sequencing offerings. Competes for genomics research budgets and offers an alternative to Illumina-based 10x workflows for certain applications.
- Bruker Corporation: Acquired NanoString Technologies and offers spatial biology products (CosMx, GeoMx, CellScape) directly competing with 10x's Xenium and Atera. A diversified life science tools incumbent with broader mass spectrometry and proteomics offerings.
Emerging players
- Element Biosciences: Emerging sequencing platform competitor with the AVITI system, offering lower-cost sequencing that could disrupt the Illumina-anchored 10x ecosystem. Increasingly competitive in academic and translational sequencing markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
10X Genomics social profiles
Digital presence10X Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
10X Genomics leadership team
Management profileNumber of profiles
Profiles13 records
10X Genomics subsidiaries and ownership
Company hierarchySubsidiaries1 record
10X Genomics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
10X Genomics M&A and investment
M&A and investmentM&A7 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 10X Genomics
What does 10X Genomics do?
10X Genomics develops and commercializes integrated platforms for single-cell and spatial biology, combining proprietary instruments (Chromium, Atera, Xenium, Visium), assay chemistries (Flex, Universal 3'/5', Epi), and software (Cell Ranger, Loupe Browser, Cloud Analysis, Space Ranger, Xenium Explorer). Products enable researchers to profile gene expression at single-cell resolution across thousands of samples, supporting cancer research, immunology, neuroscience, drug discovery, and translational medicine applications. Revenue is generated through instrument sales and a recurring consumables and software stream tied to installed platforms.
Is 10X Genomics a public or private company?
10X Genomics is a public company. It is classified as public and is currently operating.
When was 10X Genomics founded?
10X Genomics was founded in 2015. It employs 1,001 to 5,000 people.
Where is 10X Genomics based?
10X Genomics is headquartered in Pleasanton, United States, in the North America region.
How does 10X Genomics make money?
Four revenue lines are on record. Instrument Sales are the primary driver. The others are consumables, software and Analysis and CLIA Laboratory Services.
Who are 10X Genomics's main competitors?
Direct peers on record are NanoString Technologies (acquired by Bruker), Vizgen, Akoya Biosciences, Bio-Techne and Standard BioTools (formerly Fluidigm). Broad incumbents are Illumina, Revvity (formerly PerkinElmer Life Sciences), Pacific Biosciences and Bruker Corporation. Element Biosciences is listed as an emerging player.
Does 10X Genomics have an API?
No public API is recorded for 10X Genomics.
What industry is 10X Genomics in?
10X Genomics's product category is Life Sciences Research Instrumentation. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.